ReviewInternational journal of impotence research2026
Variations in diagnostic criteria for male hypogonadism: is there a need for standardizing specialist society guidelines?
Review in International journal of impotence research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Male hypogonadism or testosterone deficiency is characterized by impaired testicular function resulting in reduced androgen production and altered spermatogenesis. The prevalence of late-onset hypogonadism is approximately 2.1% among men aged 40-79 years but it can reach 30% in specific populations. Despite its clinical impact and a market projected to reach $5.1 billion by 2030, there are discrepancies among specialist societies regarding nomenclature, diagnostic cutoffs, and classification. This narrative review discusses the guidance from: the European Association of Urology (EAU), American Urological Association (AUA), Endocrine Society (EnS), Society for Endocrinology (SfE), European Academy of Andrology (EAA), British Society for Sexual Medicine (BSSM), Italian Society of Andrology and Sexual Medicine (SIAMS), Italian Society of Endocrinology (SIE), and the International Society for Sexual Medicine (ISSM). Societies approach the condition differently in terms of nomenclature (Male Hypogonadism vs Testosterone Deficiency), classification, biochemical criteria, and follow-up protocols. Some organizations, including the EAU, SfE, SIAMS & SIE, favour "male hypogonadism," spotlighting diminished testicular function in both testosterone and sperm production. Others, like the AUA, BSSM, and ISSM, prefer "Testosterone Deficiency," emphasizing symptomatic low Testosterone levels. Classifications often distinguish primary from secondary causes, but several guidelines adopt categories such as functional or compensated hypogonadism. Finally, divergent diagnostic cutoffs for total and free testosterone create "gray zones" and differing follow-up recommendations-particularly around Prostatic Specific Antigen (PSA) and haematocrit (Hct)-underscore the need for standardization. As these inconsistencies may affect clinical practice and research, consensus-based, collaborative efforts from international expert panels are needed to establish universally accepted guidelines that address the current variability in male hypogonadism.
Indexed as
Identifiers
40683978What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.